-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On AN2 Therapeutics with Buy Rating, Announces Price Target of $9

Benzinga·07/20/2026 12:03:52
Listen to the news
Guggenheim analyst Brad Canino initiates coverage on AN2 Therapeutics (NASDAQ:ANTX) with a Buy rating and announces Price Target of $9.